Results from Arm A of Phase 1/2 DREAMM-6 trial: belantamab mafodotin with lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma

1

Belantamab mafodotin is a novel monoclonal antibody conjugate showing promise in treating relapsed/refractory multiple myeloma.
2

The Phase 1/2 DREAMM-6 trial evaluated belantamab mafodotin combined with lenalidomide and dexamethasone in patients with prior therapy.
3

Overall response rate (ORR) was 67%, with a complete response rate (CRR) of 29% among the treated patients.
4

Ocular adverse events were common, with 80% of patients experiencing them, predominantly keratopathy and reduced visual acuity.
5

Median progression-free survival (PFS) for the all-treated population was 18.4 months, indicating potential efficacy of the combination therapy.

Blood Cancer Journal

by Rakesh Popat, Bradley Augustson, Mercedes Gironella, Cindy Lee, Paul Cannell, Nashita Patel, Ravi S. Kasinathan, Rachel Rogers, Mehreen Shaikh, Amy Curry, Fernando Carreño, Sumita Roy-Ghanta, Joanna Opalinska, Hang Quach
October 21, 2024

1